US Department of Defense awards Ology Bioservices $27m contract

The contract has been established for Ology to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases

US Department of Defense awards Ology Bioservices m contract

The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices a biologics CDMO.

The contract with the US-based company is to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.

Peter Khoury, President and CEO of Ology Bioservices, said: "The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases."

Khoury explained: "There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint."

You may also like